State of the Art REVIEW
146 Merrill JT, Werth VP, Furie R, et al. Phase 2 trial of iberdomide in systemic lupus erythematosus. N Engl J Med 2022;386:1034-45. doi:10.1056/NEJMoa2106535. 147 Morand E, Pike M, Merrill JT, et al. Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase ii, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol 2023;75:242-52. doi:10.1002/art.42391. 148 Cardiel MH, Tumlin JA, Furie RA, Wallace DJ, Joh T, Linnik MD, LJP 394-90-09 Investigator Consortium. Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial. Arthritis Rheum 2008;58:2470-80. doi:10.1002/ art.23673 149 Rovin BH, Furie R, Latinis K, et al, LUNAR Investigator Group. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012;64:1215-26. doi:10.1002/art.34359. 150 Furie R, Nicholls K, Cheng TT, et al. Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study. Arthritis Rheumatol 2014;66:379-89. doi:10.1002/art.38260. 151 Furie R, Rovin BH, Houssiau F, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med 2020;383:1117- 28. doi:10.1056/NEJMoa2001180. 152 Rovin BH, Solomons N, Pendergraft WF3rd, et al, AURA-LV Study Group. A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. Kidney Int 2019;95:219-31. doi:10.1016/j.kint.2018.08.025. 153 Rovin BH, Teng YKO, Ginzler EM, et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2021;397:2070-80. doi:10.1016/S0140- 6736(21)00578-X. 154 Jayne D, Rovin B, Mysler EF, et al. Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis. Ann Rheum Dis 2022;81:496-506. doi:10.1136/ annrheumdis-2021-221478. 155 Furie RA, Aroca G, Cascino MD, et al. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2022;81:100-7. doi:10.1136/annrheumdis-2021-220920. 156 Furie R, Werth VP, Merola JF, et al. Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus. J Clin Invest 2019;129:1359-71. doi:10.1172/JCI124466. 157 Sontheimer C, Liggitt D, Elkon KB. Ultraviolet B irradiation causes stimulator of interferon genes-dependent production of protective type I interferon in mouse skin by recruited inflammatory monocytes. Arthritis Rheumatol 2017;69:826-36. doi:10.1002/art.39987. 158 Sarkar MK, Hile GA, Tsoi LC, et al. Photosensitivity and type I IFN responses in cutaneous lupus are driven by epidermal-derived interferon kappa. Ann Rheum Dis 2018;77:1653-64. doi:10.1136/ annrheumdis-2018-213197. 159 Das A, Heesters BA, Bialas A, et al. Follicular dendritic cell activation by TLR ligands promotes autoreactive B cell responses. Immunity 2017;46:106-19. doi:10.1016/j.immuni.2016.12.014. 160 Caielli S, Cardenas J, de Jesus AA, et al. Erythroid mitochondrial retention triggers myeloid-dependent type I interferon in human SLE. Cell 2021;184:4464-4479.e19. doi:10.1016/j.cell.2021.07.021. 161 Raghunath S, Guymer EK, Glikmann-Johnston Y, et al. Fibromyalgia, mood disorders, cognitive test results, cognitive symptoms and quality of life in systemic lupus erythematosus. Rheumatology (Oxford) 2022;62:190-9. doi:10.1093/rheumatology/keac207. 162 Golder V, Ooi JJY, Antony AS, et al. Discordance of patient and physician health status concerns in systemic lupus erythematosus. Lupus 2017;32:961203317722412-506. doi:10.1177/0961203317722412. 163 Tsokos GC. Systemic lupus erythematosus. N Engl J Med 2011;365:2110-21. doi:10.1056/NEJMra1100359. 164 Hanly JG, Gordon C, Bae SC, et al. Neuropsychiatric events in systemic lupus erythematosus: predictors of occurrence and resolution in a longitudinal analysis of an international inception cohort. Arthritis Rheumatol 2021;73:2293-302. doi:10.1002/art.41876. 165 Raghunath S, Glikmann-Johnston Y, Hanly JG, et al. Cognitive dysfunction in systemic lupus erythematosus: how do we advance our understanding? Lancet Rheumatol 2022;4:e293-302. doi:10.1016/S2665-9913(21)00331-3. 166 Nikpour M, Urowitz MB, Ibañez D, Gladman DD. Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus. Arthritis Rheum 2009;61:1152-8. doi:10.1002/art.24741. 167 Mina R, Brunner HI. Update on differences between childhood- onset and adult-onset systemic lupus erythematosus. Arthritis Res Ther 2013;15:218. doi:10.1186/ar4256. 168 Knight JS, Branch DW, Ortel TL. Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management. BMJ 2023;380:e069717. doi:10.1136/bmj-2021-069717.
128 Isenberg DA, Petri M, Kalunian K, et al. Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis 2016;75:323-31. doi:10.1136/ annrheumdis-2015-207653. 129 Merrill JT, van Vollenhoven RF, Buyon JP, et al. Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis 2016;75:332-40. doi:10.1136/annrheumdis-2015-207654. 130 Merrill JT, Wallace DJ, Wax S, et al. Efficacy and safety of atacicept in patients with systemic lupus erythematosus: results of a 24- week randomized, placebo-controlled, phase IIb study. Arthritis Rheumatol 2017;70:266-76. doi:10.1002/art.40360. 131 Furie RA, Leon G, Thomas M, et al, PEARL-SC Study. A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate- to-severe systemic lupus erythematosus, the PEARL-SC study. Ann Rheum Dis 2015;74:1667-75. doi:10.1136/ annrheumdis-2013-205144. 132 Merrill JT, Shanahan WR, Scheinberg M, Kalunian KC, Wofsy D, Martin RS. Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo- controlled trial. Ann Rheum Dis 2018;77:883-9. doi:10.1136/ annrheumdis-2018-213032. 133 Kalunian KC, Merrill JT, Maciuca R, et al. A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE). Ann Rheum Dis 2016;75:196-202. doi:10.1136/annrheumdis-2014-206090. 134 Khamashta M, Merrill JT, Werth VP, et al, CD1067 study investigators. Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double- blind, placebo-controlled study. Ann Rheum Dis 2016;75:1909-16. doi:10.1136/annrheumdis-2015-208562. 135 Furie R, Khamashta M, Merrill JT, et al, CD1013 Study Investigators. Anifrolumab, an anti-interferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol 2017;69:376-86. doi:10.1002/art.39962. 136 Wallace DJ, Dörner T, Pisetsky DS, et al. Efficacy and safety of the Bruton’s tyrosine kinase inhibitor evobrutinib in systemic lupus erythematosus: results of a phase II, randomized, double-blind, placebo-controlled dose-ranging trial. ACR Open Rheumatol 2023;5:38-48. doi:10.1002/acr2.11511. 137 Isenberg D, Furie R, Jones NS, et al. Efficacy, safety, and pharmacodynamic effects of the Bruton’s tyrosine kinase inhibitor fenebrutinib (GDC-0853) in systemic lupus erythematosus: results of a phase II, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol 2021;73:1835-46. doi:10.1002/art.41811 138 Furie RA, Bruce IN, Dörner T, et al. Phase 2, randomized, placebo- controlled trial of dapirolizumab pegol in patients with moderate- to-severe active systemic lupus erythematosus. Rheumatology (Oxford) 2021;60:5397-407. doi:10.1093/rheumatology/ keab381. 139 Werth VP, Fleischmann R, Robern M, et al. Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study. Rheumatology (Oxford) 2022;61:2413-23. doi:10.1093/rheumatology/keab685 140 van Vollenhoven RF, Hahn BH, Tsokos GC, et al. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study. Lancet 2018;392:1330-9. doi:10.1016/S0140-6736(18)32167-6. 141 van Vollenhoven RF, Kalunian KC, Dörner T, et al. Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus. Ann Rheum Dis 2022;81:1556-63. doi:10.1136/ard-2022-222858. 142 Morand EF, Vital EM, Petri M, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I). Lancet 2023;401:1001-10. doi:10.1016/S0140-6736(22)02607-1. 143 Petri M, Bruce IN, Dörner T, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II). Lancet 2023;401:1011-9. doi:10.1016/S0140-6736(22)02546-6. 144 Furie RA, van Vollenhoven RF, Kalunian K, et al, LILAC Trial Investigators. Trial of anti-BDCA2 antibody litifilimab for systemic lupus erythematosus. N Engl J Med 2022;387:894-904. doi:10.1056/NEJMoa2118025. 145 Werth VP, Furie RA, Romero-Diaz J, et al, LILAC Trial Investigators. Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus. N Engl J Med 2022;387:321-31. doi:10.1056/ NEJMoa2118024.
18
doi: 10.1136/bmj-2022-073980 | BMJ 2023;383:073980 | the bmj
Powered by FlippingBook